We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Controlled Esophageal Stent System Aids Precise Placement

By HospiMedica staff writers
Posted on 30 Jun 2008
A new minimally invasive esophageal stent system helps improve the quality of life of terminal patients with an advanced esophageal cancer, allowing them to eat normally instead of through a tube.

The Evolution controlled release esophageal stent system incorporates a retractable delivery system that facilitates direct monitoring of the placement progress throughout the procedure, allowing physicians more controlled placement of the stent. More...
Each squeeze of the stents trigger-based introducer deploys or recaptures a proportional length of the stent. The bi-directional button enables seamless switching from deployment to recapture mode and a "point-of-no-return” mark alerts the physician when recapture is no longer available; however, even after this point is reached, repositioning is still an option. The Evolution stent is designed with dual flanges that secure the stent, potentially reducing the risk of migration or stent movement after placement, thus eliminating the need for repeat procedures. The stent also possesses both an internal and external silicone coating, designed to resist tumor growth into the stent and enhance the patients' ability to swallow food normally. The Evolution controlled release esophageal stent system is a product of Cook Medical (Bloomington, IN, USA), and has been approved by the U.S. Food and Drug Administration (FDA); the system has also received the European Community CE marking.

"We are thrilled to introduce Evolution to the market as the first and only recapturable stent deployment system,” said Barry Slowey, vice president of global sales and marketing for Cook Medical's endoscopy division. "Since launching the first esophageal stent more than 20 years ago, Cook has continued to pioneer new innovations in this market with the goal of improving patient care. With a unique set of features, like the ability to recapture, reposition, and control the deployment of the stent, Evolution leapfrogs any other esophageal stent system on the market today.”

Esophageal cancer tumors usually lead to dysphagia (difficulty in swallowing), pain, and other symptoms, and are diagnosed via biopsy. Small and localized tumors are treated surgically; larger tumors tend not to be operable and hence cannot be cured; their growth, however, can still be delayed with chemotherapy, radiotherapy, or a combination of the two. In some cases chemo- and radiotherapy can render these larger tumors operable. Prognosis depends on the extent of the disease and other medical problems, but is fairly poor. Risk factors for esophageal cancer include alcohol consumption, lye indigestion, tobacco, gastroesophageal reflux disease (GERD) and obesity. Typically, an esophageal stent is used in the treatment of esophageal cancer patients whose condition has advanced beyond surgical treatment options.


Related Links:
Cook Medical

Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.